Following the positive proof-of-concept data released in 2016, Ixchelsis is pleased to announce the start of the Phase II B dose range-finding study for IX-01 in February 2017. The study is a US based, double-blind, placebo-controlled multicentre trial assessing the efficacy of IX-01 across several doses in patients with severe lifelong PE. The study is due to complete recruitment later this year. For further information please see: https://www.clinicaltrials.gov/ct2/results?term=NCT03055806&Search=Search .
February 2017: Ixchelsis Announces Start of Phase II B Dose Range-Finding Study for IX-01
March 9, 2017 by
